FDA rejects Osteal Therapeutics' Nexchange Kit antibiotic combo for joint-implant infections, citing trial-design flaws and fungal PJI risk.
August 20, 2026 01:38 PM EDT
Pharma
FDA rejects Osteal combo therapy to treat joint-implant infections
Zachary Brennan
The FDA late last month rejected Osteal Therapeutics’ lead combo therapy that sought to more quickly fight the bacteria or other microorganisms that infect the …
Onkos Surgical® Receives FDA 510(k) Clearance for Application of NanoCept® Antibacterial Technology to Titanium Implants in the…
After Unicycive Therapeutics had its drug application for oxylanthanum carbonate (OLC)
The FDA has declined to approve Sobi’s investigational infusion of nanoencapsulated sirolimus plus pegadricase for adults with…
The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech has…
Sobi’s plan to introduce a challenger to Amgen’s blockbuster gout drug Krystexxa has been put on hold by the FDA. | Sobi’s plan…
OS Therapies shares rise after OST-HER2 Phase 2b data showed a 75% survival rate and progress toward FDA, EMA and TGA regulatory…
